Systematic Literature Review on the Efficacy of Sofosbuvir–Daclatasvir With or Without Ribavirin in the Treatment of Hepatitis C
Main Article Content
Abstract
Hepatitis C is a global infection that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. This study systematically evaluates the effectiveness of Sofosbuvir-Daclatasvir with or without Ribavirin using a Systematic Literature Review (SLR) approach following PRISMA guidelines. Database searches were conducted in the Cochrane Library and PubMed using predefined keywords, and eligible experimental or observational studies reporting SVR12 outcomes were included. Data screening, selection, and extraction were performed based on patient characteristics, treatment regimens, and outcome reporting. Analysis of six included studies shows consistently high treatment effectiveness, with SVR12 rates exceeding 90%. However, variations in response were observed in patients with advanced disease or comorbidities. The findings highlight strong overall efficacy but also emphasize the need for larger randomized clinical trials to validate these results and compare them with newer DAA regimens.
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Bhattacharya, D., Aronsohn, A., Price, J., lo Re, V., Heald, J., Demisashi, G., Durzy, E., Davis-Owino, A., & Tynes, S. (2023). Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad319
Butt, N., Akbar, A., Abbasi, A., Reema, S., Baqar, J. bin, & Shaikh, Q. H. (2019). Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience. Cureus. https://doi.org/10.7759/cureus.4012
Cui, F., Blach, S., Manzengo Mingiedi, C., Gonzalez, M. A., Sabry Alaama, A., Mozalevskis, A., Séguy, N., Rewari, B. B., Chan, P. L., Le, L. vi, Doherty, M., Luhmann, N., Easterbrook, P., Dirac, M., de Martel, C., Nayagam, S., Hallett, T. B., Vickerman, P., Razavi, H., … Low-beer, D. (2023). Global reporting of progress towards elimination of hepatitis B and hepatitis C. The Lancet Gastroenterology and Hepatology, 8(4), 332–342. https://doi.org/10.1016/S2468-1253(22)00386-7
di Marco, L., la Mantia, C., & di Marco, V. (2022). Hepatitis C: Standard of Treatment and What to Do for Global Elimination. In Viruses (Vol. 14, Issue 3). MDPI. https://doi.org/10.3390/v14030505
El-Kassas, M., Emadeldeen, M., Hassany, M., Esmat, G., Gomaa, A. A., El-Raey, F., Congly, S. E., Liu, H., & Lee, S. S. (2023). A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C. Journal of Hepatology, 79(2), 314–320. https://doi.org/10.1016/j.jhep.2023.04.011
Hyppolito, E. B., Ramos, A. N., Teixeira, L. P., Bezerra, A. M., Mendes, L. A., Silva, T. L., Lima, J. M. de C., de Arruda, É. A. G., Guerra, E. J., Tavares, M. M. S., Lima, C. E. P., Esmeraldo, T. M., Pessoa, F. S. R. de P., Pierre, A. M. M., Pereira, K. B., Filho, A. H. A., Linhares, L. M. C., Ferreira, A. F., & Neto, R. da J. P. (2024). Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil. Revista Da Sociedade Brasileira de Medicina Tropical, 57. https://doi.org/10.1590/0037-8682-0192-2024
Margusino-Framiñán, L., Cid-Silva, P., Rotea-Salvo, S., Mena-De-Cea, Á., Suárez-López, F., Vázquez-Rodríguez, P., Delgado-Blanco, M., Sanclaudio-Luhia, A. I., Martín-Herranz, I., & Castro-Iglesias, Á. (2020). Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. European Journal of Hospital Pharmacy, 27(1 e), E41–E47. https://doi.org/10.1136/ejhpharm-2019-002060
Merat, S., Sharifi, A. H., Poustchi, H., Hajiani, E., Gharavi, A., Karimi, J., Mansour-Ghanaei, F., Fattahi, M. R., Ahmadi, L., Somi, M. H., Kalantari, H., Ghadir, M. R., Sheikhesmaeili, F., Baniasadi, N., Sohrabi, M., Moosavy, S., Ziaee, M., Zahedi, M. J., Mokhtare, M., … Malekzadeh, R. (2020). SD1000: High sustained viral response rate in 1361 patients with hepatitis c genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: A multicenter, phase III clinical trial. Clinical Infectious Diseases, 70(10), 2206–2212. https://doi.org/10.1093/cid/ciz628
Sacco, R., Messina, V., Gentilucci, U. V., Adinolfi, L. E., Ascione, A., Barbarini, G., Barlattani, A., Cariti, G., Cozzolongo, R., Fimiani, B., Francavilla, R., Furlan, C., Garrucciu, G., Iovinella, V., Rinaldi, L., Marignani, M., Begini, P., Palitti, V. P., Pellicelli, A. M., … Izzi, A. (2020). Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: A large, field-practice study. Drugs in Context, 9, 1–6. https://doi.org/10.7573/dic.2020-4-11
Sheikh, N. T., Shaukat, M. T., Hussain, A., Ayyan, A., Iqbal, A., Karim, S., Ilyas, H., Ullah, K., Tahir, M. J., & Asghar, M. S. (2022). SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study. Annals of Medicine and Surgery, 80. https://doi.org/10.1016/j.amsu.2022.104193
Victor, L., Perez, R., Fernandes, F., Piedade, J., Villela-Nogueira, C. A., & Pereira, G. (2022). Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort. Medicine (United States), 101(35), E30097. https://doi.org/10.1097/MD.0000000000030097
Kementerian Kesehatan Republik Indonesia. (2023). Ayo deteksi dini hepatitis. Kementerian Kesehatan RI. . (n.d.).
Roudot-Thoraval, F. (2020). Epidemiology of Hepatitis C virus infection. https://www.sciencedirect.com/science/article/pii/S2210740120303624
Thompson, W. W., Symum, H., Sandul, A., Gupta, N., Patel, P., Nelson, N., Mermin, J., & Wester, C. (2022). MMWR, Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020. https://stacks.cdc.gov/view/cdc/119619
Tirmizi, S. (2024, July 26). Kementerian Kesehatan Republik Indonesia. (2023). Angka hepatitis B dan C di Indonesia turun. Kementerian Kesehatan RI.